

Mechanistic study of the radical SAM-dependent amine dehydrogenation reactions

Xinjian Ji, Wan-Qiu Liu, Shuguang Yuan, Yue Yin, Wei Ding, and Qi Zhang*

Instrumentation

High-performance liquid chromatography (HPLC) was performed using a Thermo Scientific Dionex Ultimate 3000 system with a diode array detector equipped with a C18 column (AccucoreXL C18, Thermo Scientific, 4.6 x 260 mm, 1.8 μ m particle size). High resolution mass spectrometry (HR-MS) analysis was performed using a Q-ExactiveTM Focus Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo Fisher) equipped with a Dionex Ultimate 3000 HPLC system (Thermo Fisher). NMR spectra were recorded using Bruker 400 MHz NMR spectrometer at the Nuclear Magnetic Resonance Facility at Fudan University. PCR was performed on a Bio-Rad T100TM Thermal Cycler using PrimeSTAR[®] HS DNA Polymerase (Takara Biotechnology Co. Ltd, China) or Phanta Max Super-Fidelity DNA Polymerase (Vazyme Biotech Co. Ltd, China).

Chemicals and Biochemicals

All chemical reagents and anhydrous solvents were purchased from commercial sources and used without further purification unless otherwise specified. S-adenosyl-L-methionine (SAM) were purchased from Sangon Biotech Co. Ltd (Shanghai, China). Pyridoxal-5-phosphate (PLP), L-Trp, D-Trp, L-Tyr, Fe(NH₄)₂(SO₄)₂•6H₂O and Na₂S were from Adamas Reagent Co. Ltd (Shanghai, China). [²H₇]-L-Tyr and [²H₈]-L-Trp were from Cambridge Isotope Laboratories, Inc (USA).

Construction of the ThiH expression plasmid

The *thiH* gene was amplified from the genomic DNA of *Escherichia coli* BL21 (DE3) using primers *thiH-F* and *thiH-R* (**Supplementary Table 1**). The PCR amplified product was digested with *EcoRI* and *HindIII*, purified using a Qiagen PCR purification kit, and inserted into the same restriction site of the expression vector pET28a (Novagen). Chemically competent *E. coli* DH5 α

cells were transformed with the ligation mixture and plated on LB-agar containing kanamycin (50/μg mL) to screen for positive clones, which were confirmed by DNA sequencing.

Construction of the plasmid for expressing low-specificity amino acid racemase (Alr)

The *alr* gene was amplified from the genomic DNA of *Pseudomonas putida* using primers *alr-F* and *alr-R* (**Supplementary table 1**). The PCR amplified products were purified and inserted into the NdeI/XhoI restriction site of pET28a (Novagen) by homologous recombination using ClonExpress II One Step Cloning Kit (Vazyme Biotech Co., Ltd). Typically, 20 μL of a mixture containing 4 μL of 5×CE II Buffer, 2 μL of Exnase II, ~50 ng linear plasmid, ~100 ng PCR fragment and ddH₂O was incubated at 37°C for 30 min, and the resulting solution was used to transform chemically competent *E. coli* DH5α cells. Colony PCR and sequencing were carried out to confirm the sequence fidelity of the recombinant plasmid.

Construction of the ThiH-R301K and NosL-R323K expression plasmid

Mutants were constructed using the one-step site-directed mutagenesis method. Briefly, two fragments were amplified from the plasmid ThiH-pET28a using a primer pair *ThiH-F1* and *ThiH-R301K-R*, and a primer pair *ThiH-R301K-F* and *ThiH-R1* (**Supplementary Table 1**), respectively. The resulting PCR products were cloned into pET28a by homologous recombination using ClonExpress MultiS One Step Cloning Kit (Vazyme Biotech Co., Ltd). 20 μL reaction mixture containing 4 μL 5×CE MultiS Buffer, 2 μL Exnase MultiS, ~50 ng linear pET28a plasmid (pre-digested with NdeI/XhoI), ~20 ng fragment 1 (~ 900 bp), ~10 ng fragment 2 (~ 280 bp) and ddH₂O, was incubated at 37°C for 30 min. Chemically competent *E. coli* DH5α cells were transformed with the ligation mixture and plated on LB-agar containing kanamycin (50 μg/mL) to screen for positive clones, which were confirmed by DNA sequencing. NosL-R323K expression plasmid was constructed in a way similar to that for ThiH-R301K, using the previously constructed NosL-expressing plasmid¹ as the PCR template.

Protein Expression

E. coli BL21 (DE3) cells were transformed via electroporation with each expression plasmid. A single colony transformant was used to inoculate a 5 mL LB culture supplemented with 50 µg/mL kanamycin. The culture was grown at 37 °C for 12 h and was used to inoculate 1 L of LB medium containing 50 µg/mL kanamycin. Cells were grown at 37 °C and 180 rpm to an OD₆₀₀ 0.6-0.8, and IPTG was then added to a final concentration of 0.2 mM. To express NosL, ThiH and their mutant enzymes, sterilized Fe(NH₄)₂(SO₄)₂ solution was added to the culture to a final concentration of 100 µM. After additional 18 h of incubation at 20 °C and 130 rpm, the cells were harvested by centrifugation at 5000 rpm for 15 min at 4 °C. The pellet was used directly for protein purification or stored at –80 °C upon further use.

Purification of Alr

Alr was purified aerobically. The cell pellet collected by centrifugation was re-suspended in 40 ml lysis buffer (50 mM MOPS, 200 mM NaCl, and 10% glycerol, pH 8.0), and was lysed by sonication on ice. Cell debris was removed via centrifugation at 14000 rpm for 30 min at 4 °C. The supernatant was incubated with 4 ml Ni-NTA resin pre-equilibrated with the lysis buffer, and then subjected to affinity purification on a column. The desired elution fractions were combined and concentrated using an Amicon Ultra-15 Centrifugal Filter Unit, and the concentrated protein solution was desalted by using a PD-10 column (GE Healthcare) pre-equilibrated with the elution buffer I (50 mM MOPS, 25 mM NaCl, and 10% (v/v) glycerol in deuterium oxide (~90%), pD 8.0). The protein fraction was collected and concentrated, analyzed by SDS-PAGE (12% Tris-glycine gel), and was used directly for in vitro assay or stored at –80 °C upon further use. Protein concentration was determined using a Bradford Assay Kit (Bio-Rad) using bovine serum albumin (BSA) as a standard.

Preparation of the reconstituted NosL, ThiH and mutant enzymes

Protein purification and [4Fe-4S] reconstitution were performed in an anaerobic glove box (Coy Laboratory Product Inc., USA) with less than 2 ppm of O₂. The cell pellet was resuspended in

20ml of the lysis buffer (50 mM MOPS, 200 mM NaCl, and 10% glycerol, pH 8.0), and was lysed by sonication on ice. Cell debris was removed via centrifugation at 14000 rpm for 30 min at 4 °C. The supernatant was incubated with 4 ml Ni-NTA resin pre-equilibrated with the lysis buffer, and then subjected to affinity purification on a column. The desired fractions were combined and concentrated using an Amicon Ultra-15 Centrifugal Filter Unit and analyzed by SDS-PAGE (12%Tris-glycine gel). Protein concentration was determined using a Bradford Assay Kit (Bio Rad) using bovine serum albumin (BSA) as a standard.

For reconstitution of the [4Fe-4S] clusters of NosL and ThiH, freshly prepared dithiothreitol (DTT) was added to the purified protein fraction to a final concentration of 5 mM. $\text{Fe}(\text{NH}_4)_2(\text{SO}_4)_2$ solution (50 mM) was then added carefully to a final concentration of 500 μM . After 10 min of incubation at the room temperature, Na_2S solution (50 mM) was added in the same way to a final concentration of 500 μM . After further incubation on ice for 5-7 h, the resulting blackish solution was subjected to desalting on a PD-10 column (GE Healthcare) pre-equilibrated with the elution buffer I or elution buffer II (50 mM MOPS, 25 mM NaCl, 10 mM DTT and 10% (v/v) glycerol, pH 8.0). The protein fraction was collected and concentrated, and was used directly for in vitro assay or stored at $-80\text{ }^\circ\text{C}$ upon further use.

Enzyme assays

A typical assay was carried out by incubating 500 or 200 μM L-Trp or L-Tyr with $\sim 50\text{ }\mu\text{M}$ reconstituted protein, 500 μM SAM and 2 mM of sodium dithionite ($\text{Na}_2\text{S}_2\text{O}_4$) in 50 mM MOPS buffer (pH 8.0). Reaction volumes were typically 200 μL and were maintained at room temperature ($\sim 25^\circ\text{C}$) for 1.5 h prior to quenching. The reactions were quenched by addition of trichloroacetic acid (TCA) to a final concentration of 5% (v/v). After removal of the protein precipitates by centrifugation, the supernatant was subjected to HPLC and/or LC-MS analysis.

To explore the requirement for external reductant, 300 μL solution containing 50 μM reconstituted enzyme was supplied with 3 μL 10 mM freshly prepared sodium dithionite. The solution was incubated for 30 min at room temperature and then for 15 h at 10 °C. 10 μL of the reduced enzyme was then added to 90 μL 50 mM Tris buffer (pH 8.0) containing 1 mM DTT, 0.5 mM

SAM and 0.5 mM substrate. As a positive control, a second aliquot of 10 μ L protein solution was added to 90 μ L of the same solution that also contained 0.4 mM sodium dithionite. Following the addition of the reduced enzyme, 50 μ L aliquots were filtered to remove protein at 5 min and 5 h, and frozen prior to analysis by LC/MS. This experiment was performed in duplicates.

HPLC analysis was performed using a C18 analytic column (Accucore XL C18, Thermo Scientific, 4.6 x 250 mm). The column was equilibrated with 85% solvent A (H₂O, 0.1% TFA) and 15% solvent B (CH₃CN, 0.1% TFA), and developed at a flow rate of 1 ml/min and UV detection at 254 nm or 298 nm: 0-3 min, constant 98% A / 2% B; 3-20 min, a linear gradient to 80% A / 20% B; 20-23min, a linear gradient to 0% A /100% B; 23-28min, constant 0% A /100% B; 28-30min, a linear gradient to 90% A / 2% B.

Synthesis of D,L-[α -²H]-Trp

200 μ L reaction mixture in \sim 90% D₂O buffer containing 100 μ M L-Trp, 1 mM NADH, 1 mM PLP and \sim 50 μ M Alr were incubated at room temperature (\sim 25°C) for 5 h. The reaction was quenched by adding trichloroacetic acid (TCA) to a final concentration of 5% (v/v). After removal of the protein precipitates by centrifugation, the supernatant was analyzed directly by LC-HR-MS/MS.

Molecular Mechanical Calculations

All protein models were prepared in Schrodinger suite software under the OPLS_2005 force field.² Hydrogen atoms were added to the repaired crystal structures at physiological pH (7.4) with the PROPKA³ tool to optimize the hydrogen bond network provided by the Protein Preparation tool in Schrodinger software⁴. Asn, Gln, and His residues were checked for flips automatically in ProPrep in Schrodinger. Constrained energy minimizations were conducted on the full-atomic models, with heavy atom coverage to 0.4 Å.

The docking procedure was performed with Glide^{5, 6} (Schrödinger 2015 suite). Each ligand molecule was initially placed in the binding pocket in a pose similar to that observed in the corresponding crystal structure. Cubic boxes centered on the ligand mass center with a radius of

12 Å defined the docking binding regions before flexible ligand docking was executed. Five poses out of 20,000 per ligand were included in post-docking energy minimization. Top scored pose was exported for study.

Fig. S1. Structure characterization of the mono-deuterated Trp produced in NosL-catalyzed reaction in D₂O. (a) Theoretical MS/MS fragmentation of D,L-[α-²H]-Trp.⁷ (b) HR-MS/MS spectrum of the mono-deuterated Trp produced in the reaction with NosL and 10 μM D-Trp in D₂O buffer. (c) HR-MS/MS spectrum of the authentic D,L-[α-²H]-Trp synthesized from L-Trp using a low-specificity amino acid racemase (Alr) in D₂O buffer. (d) HR-MS/MS spectrum of the mono-deuterated Trp produced in the reaction with NosL R323K mutant and 10 μM L-Trp in D₂O buffer.




Fig. S2. Incorporation of deuterium atoms into dAdoH and L-Trp. (A) Summed MS spectrum of dAdoH produced in the reaction with the NosL R323K mutant and 500 μ M L-Trp in D₂O. (B) Summed MS spectrum of Trp in the reaction with NosL R323K mutant and 10 μ M L-Trp in D₂O.




Fig. S3. Redox stoichiometry analysis of L-Trp consumption. (a) HPLC analysis of the reaction mixture containing SAM, L-Trp and the reduced NosL wild type enzyme at (i) 5 min without external dithionite (DTH), (ii) 300 min without DTH, and (iii) 300 min with DTH. (b) LC-MS analysis of the reaction mixture containing SAM, L-Trp, and the reduced NosL R323K mutant, showing the EICs for $[M-H]^- = 202.05$ (corresponding to indole-3-pyruvate) for the reaction at (i) 5 min without DTH, (ii) 300 min without DTH, and (iii) 300 min with DTH. These analyses demonstrated that production of MIA and 3-methylindole by the NosL wild type enzyme requires external reductant whereas L-Trp amine dehydrogenation catalyzed by NosL R323K mutant does not.




Fig. S4. HPLC analysis of (4-hydroxyphenyl)-3-lactate (HPL) generated by NaBH_4 reduction of (4-hydroxyphenyl)-3-pyruvate (HPP), showing the HPLC traces of (i) HPL standard, (ii) the reaction mixture treated with NaBH_4 , and (iii) the mixture of trace ii co-injected with the authentic HPL standard.





Fig. S5. Summed MS spectrum of dAdoH produced in the reaction with ecThiH R301K mutant and [²H₇]-L-Tyr in H₂O buffer, showing that dAdoH was predominantly mono-deuterated.



Supplementary Table 1. PCR primers used in this study.

Primer	Sequence	Function
<i>thiH-F</i>	AAAAGAATTCATGAAAACCTTCAGCGATCGCTGG	ThiH cloning
<i>thiH-R</i>	AAAAAAGCTTCATGGCCTTTGCGATGGGCGTCC	
<i>alr-F</i>	CCGCGCGGCAGCCATATGATGCAATTTAGCCGTACCCTCCTGGCT GC	Alr cloning
<i>alr-R</i>	GGTGGTGGTGGTGCTCGAGTCAGTCGACGAGTATCTTCGGGTTGG AACTG	
<i>thiH-F1</i>	CCGCGCGGCAGCCATATGATGAAAACCTTCAGCGATCGCT	ThiH-R301K cloning
<i>thiH-R1</i>	GGTGGTGGTGGTGCTCGAGTCATAGTCTTTGCGAGGCGCGTC	
<i>thiH-R301K-F</i>	CCGGAGATTGAACTGTCACTCTCCACGAAAGAATCACCGTGGTTT CGCG	
<i>thiH-R301K-R</i>	GCACCGGAGATTGAACTGTCACTC	
<i>nosL-F1</i>	CCGCGCGGCAGCCATATGATGACGCAGAACTCCCAGG	NosL-R323K cloning
<i>nosL-R1</i>	GGTGGTGGTGGTGCTCGAGTCAGACCGCCCGGGACGCCTC	
<i>nosL-R323K-F</i>	GCGGCTCGTCCTCACCACGAAAGAGCCGCAGGAGTTCCAG	
<i>nosL-R323K-R</i>	CGTGGTGAGGACGAGCCGCTGCTCGGG	

References

1. X. Ji, Y. Li, W. Ding and Q. Zhang, *Angew Chem Int Ed Engl*, 2015, **54**, 9021-9024.
2. D. Shivakumar, J. Williams, Y. J. Wu, W. Damm, J. Shelley and W. Sherman, *J Chem Theory Comput*, 2010, **6**, 1509-1519.
3. C. R. Sondergaard, M. H. M. Olsson, M. Rostkowski and J. H. Jensen, *J Chem Theory Comput*, 2011, **7**, 2284-2295.
4. Schrödinger, *Journal*, 2015.
5. R. A. Friesner, J. L. Banks, R. B. Murphy, T. A. Halgren, J. J. Klicic, D. T. Mainz, M. P. Repasky, E. H. Knoll, M. Shelley, J. K. Perry, D. E. Shaw, P. Francis and P. S. Shenkin, *Journal of medicinal chemistry*, 2004, **47**, 1739-1749.
6. T. A. Halgren, R. B. Murphy, R. A. Friesner, H. S. Beard, L. L. Frye, W. T. Pollard and J. L. Banks, *Journal of medicinal chemistry*, 2004, **47**, 1750-1759.
7. H. Lioe, R. A. O'Hair and G. E. Reid, *J Am Soc Mass Spectrom*, 2004, **15**, 65-76.